Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PL
Protalix BioTherapeutics, Inc. Common Stock
PLX
Mkt Cap
$210.7M
Volume
1.15M
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PL
PLX
PL
Protalix BioTherapeutics, Inc. Common Stock
PLX
News
·
Protalix (PLX) Q2 2026 Earnings Call Transcript
Mkt Cap
$217.5M
Volume
1.15M
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Protalix (PLX) Q2 2026 Earnings Call Transcript
Protalix reported Q2 2026 revenues of $19.9 million, up from $15.7 million year-over-year, driven by Elfabrio sales through its Chiesi partnership. The company posted net income of $3.8 million ($0.05 per share) and H1 net income of $22.1 million. Full-year 2026 revenue guidance remains $78-83 million. The company maintains a strong cash position of $40.7 million with zero debt and expects PRX-115 Phase 2 RELEASE study top-line results in H2 2027.
The Motley Fool · Aug 19, 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
The European Commission has approved a new every-4-weeks dosing regimen (2mg/kg) for Elfabrio® (pegunigalsidase alfa) in adults with Fabry disease who are stable on enzyme replacement therapy. This approval extends the infusion interval from every 2 weeks, reducing treatment burden for patients and healthcare systems. Protalix is entitled to a $25 million regulatory milestone payment from Chiesi. The FDA-approved dosing in the US remains unchanged at 1mg/kg every 2 weeks.
GlobeNewswire Inc. · Mar 9, 2026
[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
The global Fabry disease treatment market is expected to grow from $2.76 billion in 2024 to $7.02 billion by 2034, at a CAGR of 9.8%. Key factors driving the market include FDA clearance of Fabry disease drugs and increased R&D investment.
GlobeNewswire Inc. · Mar 26, 2025
Pluxee to acquire Cobee, an innovative Spanish digital player in Employee Benefits
Pluxee to acquire Cobee, an innovative Spanish digital player in Employee Benefits
GlobeNewswire Inc. · Jun 12, 2024
Pluxee signe un accord pour l’acquisition de Cobee, un acteur digital espagnol innovant des avantages aux salariés
Pluxee signe un accord pour l’acquisition de Cobee, un acteur digital espagnol innovant des avantages aux salariés
GlobeNewswire Inc. · Jun 12, 2024
Pluxee firma un acuerdo para adquirir Cobee, empresa digital e innovadora de origen español especializada en beneficios para empleados
Pluxee firma un acuerdo para adquirir Cobee, empresa digital e innovadora de origen español especializada en beneficios para empleados
GlobeNewswire Inc. · Jun 12, 2024
Declaration of transactions in own shares n 2024/07
Regulated information
GlobeNewswire Inc. · Apr 22, 2024
Déclaration des transactions sur actions propres n 2024/07
Information réglementée
GlobeNewswire Inc. · Apr 22, 2024
Pluxee delivers strong performance in the First Half and raises Fiscal 2024 Organic revenue growth and Recurring EBITDA margin objectives
First Half Fiscal 2024 highlights
GlobeNewswire Inc. · Apr 19, 2024
Pluxee affiche une performance solide au premier semestre et relève ses objectifs de croissance organique du chiffre d’affaires et de marge d’EBITDA récurrent pour l’exercice fiscal 2024
Faits marquants du premier semestre de l’exercice 2024
GlobeNewswire Inc. · Apr 19, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PL
PLX
Protalix BioTherapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
PLX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PLX yet.
Related Tickers
Earnings